ENOV ENOVIS CORPORATION

Enovis to Participate in Upcoming Investor Conferences

Enovis to Participate in Upcoming Investor Conferences

Wilmington, DE, March 05, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven, medical technology growth company, today announced that its management team will participate in the following investor conferences:

  • Canaccord Genuity Musculoskeletal Conference: Ben Berry, Chief Financial Officer, and Louie Vogt, Group President - Recon, will participate in a fireside chat on Monday, March 10th at 10:00 a.m. Pacific Time.
  • 37th Annual Roth Conference: Louie Vogt, Group President - Recon, will participate in a fireside chat on Monday, March 17th at 8:30 a.m. Pacific Time.
  • 24th Annual Needham Healthcarte Conference: Ben Berry, Chief Financial Officer, will participate in a fireside chat on Tuesday, April 8th at 1:30 p.m. Eastern Time.

A link to the live audio webcasts, as well as a replay of these events, will be available on the Company’s website under the Investors tab at Events and Presentations.

ABOUT ENOVIS

Enovis Corporation (NYSE: ENOV) is an innovation-driven medical technology growth company dedicated to developing clinically differentiated solutions that generate measurably better patient outcomes and transform workflows. Powered by a culture of continuous improvement, global talent and innovation, the Company’s extensive range of products, services and integrated technologies fuels active lifestyles in orthopedics and beyond. The Company’s shares of common stock are listed in the United States on the New York Stock Exchange under the symbol ENOV.  For more information about Enovis, please visit .

Contact:

Kyle Rose

Vice President, Investor Relations

Enovis Corporation



EN
05/03/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ENOVIS CORPORATION

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: December 6, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

 PRESS RELEASE

Enovis Announces Third Quarter 2025 Results

Enovis Announces Third Quarter 2025 Results Diversified growth platform delivers third-quarter sales growth of 9% on a reported basis, 7% organically Third-quarter Reconstructive sales grew 12% year-over-year on a reported basis, 9% organically October divestiture of Diabetic Footcare business unit from P&R for total proceeds of up to $60 million Raising full-year 2025 adjusted EBITDA and adjusted EPS guidance Dallas, TX, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation (“Enovis” or “the Company”) (NYSE: ENOV), an innovation-driven medical technology growth company, today annou...

 PRESS RELEASE

Enovis announces webcast and conference call for Third Quarter 2025 Re...

Enovis announces webcast and conference call for Third Quarter 2025 Results and participation in upcoming investor conferences Dallas, TX, Oct. 24, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation (“Enovis” or “the Company”) (NYSE: ENOV), an innovation-driven medical technology growth company, announced today it will host an investor conference call and live webcast to discuss its third quarter 2025 financial results on Thursday, November 6th, 2025, at 8:30 a.m. Eastern Time and issue an earnings press release earlier that morning. A presentation related to the call, as well as a webcast, wi...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch